BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...
BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

December has been a busy month for Alzheimer’s therapies testing new hypotheses outside of amyloid, with the latest coming Wednesday from Novo Nordisk, which said it is taking semaglutide into Phase III...
BioCentury | Nov 25, 2020
Product Development

Steady stream of Phase III COVID-19 vaccine data to flow into the new year

The dizzying pace of COVID-19 vaccine readouts over the last three weeks is only going to accelerate over the next five. By the end of the year, three of the four leading vaccines are likely...
BioCentury | Oct 23, 2020

SPAC to the future: an old-time IPO alternative may be back to stay

Investors and bankers believe specialist-backed SPACs could become a cyclical part of biotech’s fund-raising equation with some clear advantages over traditional IPOs for the right type of company. But...
BioCentury | Oct 22, 2020
Product Development

CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies

CRISPR Therapeutics’ first allogeneic CAR T therapy readout supports the idea that the therapeutic class can yield efficacy on par with autologous CAR Ts, without causing graft-versus-host disease. But a patient death raises the possibility allogeneic...
BioCentury | Oct 13, 2020
Product Development

Gilead’s Jyseleca has a leg up over BMS’s Zeposia in biologic-experienced UC patients

Pivotal data in ulcerative colitis show two oral therapies — Jyseleca filgotinib from Gilead and Galapagos and Zeposia ozanimod from Bristol Myers Squibb — generating efficacy on par with biologics, with...
BioCentury | Sep 17, 2020
Product Development

Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies

Arrowhead gains on AAT deficiency dataArrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained nearly $1.4 billion in market cap Wednesday after sharing interim data from four alpha-antitrypsin (AAT) deficiency patients treated with ARO-AAT in the Phase II AROAAT2002...
BioCentury | Sep 11, 2020
Product Development

Governments must work alongside industry to fill the cracks exposed by COVID-19 before the next, inevitable, pandemic

This is the fifth and final article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient...
BioCentury | Sep 5, 2020
Product Development

Russian COVID-19 vaccine induces T cell responses, antibodies on par with convalescent plasma

Clinical readouts for Russian COVID-19 vaccine Sputnik V indicate preexisting immunity against adenoviral vectors don’t necessarily prevent vaccine-induced immune responses against SARS-CoV-2. Sputnik...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Inhibiting proteolytic activation of the receptor PAR2 for eosinophilic esophagitis

DISEASE CATEGORY: Inflammation INDICATION: Eosinophilic esophagitis Inhibiting the extracellular serine protease KLK5 or its substrate PAR2 could treat eosinophilic esophagitis, a food antigen-driven inflammatory disease. Single-cell sequencing revealed aberrant KLK5 expression in multiple cell populations...
Items per page:
1 - 10 of 687